argenx SE
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date
11 mar 2015 - 07:23
Statutory name
argenx SE
Title
arGEN-X to Host Conference Call & Webcast to Report Fourth Quarter Business Update and Full Year 2014 Financial Results on March 18, 2015
Comments
Breda, the Netherlands / Ghent, Belgium, 11 March 2015 - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it will report its fourth quarter business update and its full year 2014 financial results after market close on Wednesday, 18 March 2015.
The arGEN-X management team will host a conference call and audio webcast at 6:00pm CET (midday ET) to discuss the financial results, as well as provide a fourth quarter business update.
To participate in the conference call, please select your phone number here, and use the confirmation code 92395735. The webcast may be accessed on the homepage of the arGEN-X website at www.argen-x.com or by clicking here.
A replay of the webcast will also be available at the arGEN-X website: www.argen-x.com/reports-and-presentations/
Related downloads
Date last update: 03 April 2026